Phase I/Ib Study of Surgical Resection or Radiofrequency Ablation (RFA) of Metastatic Lesions in the Liver in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Metastatic Colorectal Cancer
Latest Information Update: 16 Feb 2022
At a glance
- Drugs MEDI 6469 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Jan 2022 Status changed from active, no longer recruiting to discontinued since study drug expired and access to additional supply ended.
- 19 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 29 Sep 2015 New trial record